Trial · NCT00692185
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
NCT00692185, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2009-07-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa. Trials, record NCT00692185. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00692185
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
- NCT number
- NCT00692185
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Eating Disorders
- Interventions
- Olanzapine, Placebo
- First posted
- 2008-06-06
- Last updated
- 2019-05-10
- Results first posted
- 2009-07-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight Gain | Measured at Week 8 | |
| Secondary | Symptom Severity Assessed by Yale Brown Cornell-Eating Disorders Scale | Measured at Week 8 | The Yale Brown Cornell-Eating Disorders Scale was used.This scale assesses severity of preoccupations and rituals. There are 8 questions that can be scored between 0-4 to indicate severity of symptoms, with 0 representing less severe and 4 representing most severe symptoms. The scores were summed, with possible results totaling 0-32. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Weight Gain | Measured at Week 8 | lbs | MEAN | |
| SECONDARY | Symptom Severity Assessed by Yale Brown Cornell-Eating Disorders Scale | Measured at Week 8 | Individuals with anorexia nervosa | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Weight Gain | Olanzapine | 6.2 | Standard Deviation 6.6 | lbs | |
| Weight Gain | Placebo | 1.5 | Standard Deviation 4.4 | lbs | |
| Symptom Severity Assessed by Yale Brown Cornell-Eating Disorders Scale | Olanzapine | 19.4 | Standard Deviation 8.1 | score on a scale | |
| Symptom Severity Assessed by Yale Brown Cornell-Eating Disorders Scale | Placebo | 18.9 | Standard Deviation 6.5 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Olanzapine | 11 | |
| Overall Study | STARTED | Placebo | 12 | |
| Overall Study | COMPLETED | Olanzapine | 8 | |
| Overall Study | COMPLETED | Placebo | 9 | |
| Overall Study | NOT COMPLETED | Olanzapine | 3 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Olanzapine | 0 | 11 |
| Total, all-cause mortality | Placebo | 0 | 12 |
| Total, other adverse events | Olanzapine | 0 | 11 |
| Total, other adverse events | Placebo | 0 | 12 |
| Total, serious adverse events | Olanzapine | 0 | 11 |
| Total, serious adverse events | Placebo | 0 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21426603 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R21MH069868 | Atypical Antipsychotic Medication in Anorexia Nervosa | ATTIA, EVELYN | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC | NATIONAL INSTITUTE OF MENTAL HEALTH | 2004 to 2006 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Olanzapine vs Placebo: deaths from any cause | Trial comparisons |
| Olanzapine vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00692185
GET https://conductscience.org/api/trials/v1/NCT00692185/registered